Podcasts about Foran

After five tumultuous years as head of Air New Zealand, CEO Greg Foran is preparing to hang up his wings this October. Between COVID-19 border closures, fleet delays, maintenance issues and other problems, it's fair to say the Kiwi flag carrier has had a rough half-decade – but how well has it weathered the storm? On location in Auckland, Australian Aviation's Jake Nelson talks to Foran about his tenure, what he might have done differently, and what might be next for the airline. Plus, Adam and Jake discuss the rest of the week's news, including Qantas' ongoing attempts to draw a line under the Joyce era. Jake Nelson travelled as a guest of Air New Zealand.

Greg Foran knew his time with Air New Zealand was limited from the get go. The outgoing CEO announced his resignation in March, planning to stay on until October. He began at Air NZ in early 2020, replacing Christopher Luxon. Foran told Mike Hosking he knew in the back of his mind he'd probably only do about five or six years with the company, as he has other things he's keen to do. He says it's been one of the peak learning experiences he's had, and he's a far better leader today than he was before he took the job. He also weighed in on the country's tourism numbers. He's been in Rotorua this week for the national tourism industry summit, TRENZ. Foran told Hosking overseas visitor arrivals last year were only 87% of pre-Covid levels in 2019. He believes by this time next year, numbers will be back over 100% compared to pre-Covid. LISTEN ABOVE See omnystudio.com/listener for privacy information.

So, after all the handwringing, the complaints, the stomping of feet, the Commerce Commission's shooting down talk of an investigation into domestic airfares. Greg Foran and Co. will see this as vindication - validation that, despite the headlines and Consumer NZ's claim the market is quote broken, the reality is their costs have gone up and, surprise surprise, it's expensive to run routes with high fixed costs to small places with few people. So they conclude doing a market study —which is easy politics, it scratches the itch— won't actually achieve anything. And they say it won't lead to consumers getting a better deal. Refreshing honesty. Could the same refreshing honesty not have been applied to the claims about banking/supermarkets/petrol stations, etc, etc, etc? Like most things post-Covid, costs have gone sky high. Airport landing charges - up. Air traffic control - up. Security levies - up. And when you're a business, one owning to the tune of 51% remember, you recoup those costs by putting your own prices up. We don't want them subsidies flights and crashing our business, right? We sold off the national carrier in 1989. We re-nationalised it in 2001after Ansett went bust - that cost us close to a billion bucks. Ansett's problem was high costs and regulation changes - when airlines fail, it gets expensive for taxpayers. Now I don't want to defend an airline charging me $400 to fly for 40 minutes anymore than the next guy. But this is the crux of most of the complaints we hear about through the media. Short flights, regional flights are expensive right now and people don't use them often enough. They use more fuel as a proportion of total flight time because take-off and climbing is when you burn through it - it takes a bit of gas to lift us into the sky. The cost of fuel is a third of operating cost —something Foran can't control— that's more the purview of a Putin or a Sultan. Planes spend way too long sitting on the ground, your costs are higher, and you've got fewer passengers to spread those costs over. Using jets would be more efficient but, again, we don't have the people to fill them. Which is why I said the other day —and it's true but doesn't make it palatable— we're a small country, we pay a price for sparsely populated, beautiful and untouched landscapes. The ComCom does say there's room for improvement, but on the whole, the real enemy here is the politician or talking head who tells us by simply bashing Air New Zealand's head into a wall, they can make Kiwis fly on the cheap.See omnystudio.com/listener for privacy information.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠It's YOUR time to #EdUpIn this episode, brought to YOU by HigherEd PodConYOUR guest is Matt Foran, Founder & CEO, KnowMeQYOUR host is ⁠⁠⁠⁠Dr. Jodi BlincoHow can AI tools transform credit for prior learning in higher education?Why is knowing oneself the most important "Q" for career success?How does simplifying prior learning assessment increase student enrollment?What role can AI play in creating equitable educational pathways?Why must institutions improve accessibility for non-traditional students & veterans?Topics include:AI-powered credit assessment solutionsRemoving barriers for adult learnersCreating educational pathways for military veteransTransforming resource-intensive processes into revenue generatorsSupporting lifelong learning through employer partnershipsListen in to #EdUpDo YOU want to accelerate YOUR professional development?Do YOU want to get exclusive early access to ad-free episodes, extended episodes, bonus episodes, original content, invites to special events, & more?Then ⁠⁠⁠⁠⁠⁠BECOME A SUBSCRIBER TODAY⁠⁠ - $19.99/month or $199.99/year (Save 17%)!Want to get YOUR organization to pay for YOUR subscription? Email ⁠⁠⁠EdUp@edupexperience.comThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Joe Sallustio⁠⁠⁠⁠● Join YOUR EdUp community at ⁠⁠⁠⁠⁠⁠⁠⁠⁠The EdUp Experience⁠⁠⁠⁠⁠⁠⁠⁠⁠!We make education YOUR business!

 In this episode of What Happens in Vagus, Dr. Stephanie Canestraro sits down with Amy (Amelia) Foran to discuss her deeply personal and transformative health journey. Amy opens up about her experience navigating over 30 persistent symptoms before discovering the healing potential of functional medicine.Together, they explore the power of identifying root causes—such as mold exposure—and how protocols like infrared sauna therapy, detox binders, and low dose immunotherapy helped Amy reclaim her health. Dr. Steph and Amy dive into the often-overlooked connections between histamine intolerance, collagen, liver function, and even dental health, emphasizing how each plays a role in chronic symptoms and overall wellness. They also highlight the importance of tuning into your body's signals, the value of preventative care, and how therapies like frequency-specific treatments and meditation can support healing. This conversation underscores the importance of self-care, being your own health advocate, and finding practitioners who truly listen. Whether you're on your own health journey or supporting someone through theirs, this episode is a reminder that chronic symptoms are rarely isolated—and healing begins when we look beneath the surface. If this episode resonates with you, we'd love to support you. Visit our website to book a FREE 20-minute session with our Health Coach. Your path to wellness starts with one small step. Follow Dr. Steph on Instagram here.Follow Vagus Clinic on Instagram here.Visit the Vagus Clinic website here.Let us know your thoughts on this episode here

Inderside med Orri Oskarsson - kan også ses på Pluto TV:https://pluto.tv/dk/on-demand/series/65279f17939c4b001a40a690/season/2/episode/67dc4c666baaac5c4605a1be Hosted on Acast. See acast.com/privacy for more information.

Inderside med Orri Oskarsson - kan også ses på Pluto TV:https://pluto.tv/dk/on-demand/series/65279f17939c4b001a40a690/season/2/episode/67dc4c666baaac5c4605a1be Hosted on Acast. See acast.com/privacy for more information.

Hanna har vært på hyttetur med managementet sitt. Her var hun livredd på randonee og i seng kl 2(!) hver kveld. Melina har også stått i bakken, men uten afterski etterpå. Tema for ukas episode er eksponering av barn i sosiale medier. Hvor går grensa? Er det "nørd" å legge emoji foran ansiktet til barna? Og hva er det viktigste å tenke på her? Gi oss gjerne tilbakemeldinger. God lytt!See omnystudio.com/listener for privacy information.

Tiden er endelig kommet - Elite/serien 2025 er i gang om få dager, og da er det jo tid for å se på tingenes tilstand og sparke igang podcast-sesongen for alvor. Vi går gjennom stallen og snakker om våre egne forventninger til sesong to av Alfreds Rosenborg. Vi var det beste laget i serien de siste 21 serierundene i fjor - klarer vi å bygge videre på dette i år? Det blir tid for en liten Klaveness-basert boikott og en kjapp titt på damene som virker å være på nedadgående før vi gir oss for kvelden.  Vi er med dette tilbake til ukentlige episoder, med mulige opphold for de forbanna landslagspausene som dukker opp i... utide. Vil du delta i vår Fantasy-liga for Elite/serien 2025 gjør du det her! Vil du kjøpe Troillprat-merch kan du gjøre det her. Hvis du ønsker å komme med innspill til Troillprat i sanntid er det mulig å se oss live på Twitch, YouTube, Twitter eller Facebook når vi spiller inn tirsdager. Link til dette kommer typisk i løpet av timen før opptak starter kl. 20 på RBKweb-forumet, Bluesky, Twitter, Facebook og vår Discord-server.

Måske er du stødt på Pernille Knudsen i medierne. Hun er viceadministrerende direktør i Dansk Arbejdsgiverforening. Og når hun taler offentligt som en del af sit job, handler det normalt om arbejdsmarkedet. Men i det her afsnit bliver det mere personligt. For her fortæller Pernille, hvordan det er at være hende og sidde som topchef midt i vigtige forhandlinger og få en kæmpe hedetur. Altså sidde og blive helt rød i hovedet, mens vandet løber ned langs hårgrænsen, indtil det drypper ned på papirerne på bordet. Foran alle. Dét fortæller hun om. Hun kan nemlig ikke holde ud at skamme sig over en livsfase, som alle kvinder skal igennem. Så hun siger det højt. Også for at hjælpe andre i samme situation. Hun taler om … overgangsalderen.See omnystudio.com/listener for privacy information.

"Hold da kæft mand. Det er det vildeste, jeg nogensinde har set. Er du helt straight i hovedet?" Remee er nærmest i chok. Han har lige overværet en audition, han sent vil glemme. Foran ham, Lina Rafn og Thomas Blachmann, står den 19-årig fynske Andreas med et skævt smil og er igang med at charmere sig videre i X Factor. Men hvad, han ikke ved, er, at det her skal blive det første af 7 nederlag. Vært: Pelle Peter Jencel. Klipper: Ole Fugl. Lyddesign: Jakob Franck Jensen. Redaktør Morten Narvedsen. Redaktionsleder: Anders Stegger.

"Hold da kæft mand. Det er det vildeste, jeg nogensinde har set. Er du helt straight i hovedet?" Remee er nærmest i chok. Han har lige overværet en audition, han sent vil glemme. Foran ham, Lina Rafn og Thomas Blachmann, står den 19-årig fynske Andreas med et skævt smil og er igang med at charmere sig videre i X Factor. Men hvad, han ikke ved, er, at det her skal blive det første af 7 nederlag. Vært: Pelle Peter Jencel. Klipper: Ole Fugl. Lyddesign: Jakob Franck Jensen. Redaktør Morten Narvedsen. Redaktionsleder: Anders Stegger.

How is PVStop training first responders and electrical technicians to safely handle solar panels? Hello Smart Firefighting Community! Welcome to another episode of covering real world innovations via interviews with fire service and technology industry experts that empower YOU to develop your very own Smart Firefighting strategy! In this episode: A liquid blanket that de-energizes solar panels, making them safe for emergency response PVStop's new drone delivery system for high-rise and difficult-to-access solar installations The potential for collaboration with insurers to enhance solar safety measures Hear from Jim Foran - the Director at PVStop International Pty Ltd. Jim shares their innovative approach to making solar energy safe for firefighters and first responders. Their flagship product, PVStop, acts as a liquid blanket that can be sprayed onto solar panels, blocking light and de-energizing the panels to create a safe working environment during emergencies. They introduce their new drone delivery system, designed to spray the coating on solar panels in hard-to-reach areas like high-rises.  The discussion also covers PVStop's commitment to providing training and education tools for first responders and electrical technicians, ensuring safe practices around solar installations. Additionally, they are exploring partnerships with early detection companies to prevent electrical incidents from escalating into fires. So take a listen to hear what he has to share!  Episode Resources: AFAC25 Conference Head to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartfirefighting.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to discover how SFF accelerates innovation for emergency responders, to find out when our next event is, or review our curated resources! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠

In the wake of the resignation of Greg Foran from Air NZ Steve and Seamus talk about the 'Between Two Beers Curse' and if Paddy Gower belongs in the conversation.They also talk about how many haircuts Steve has left, how they get guests, answer questions from the audience, and reminisce on nights at The Outback Inn.

Velkommen tilbake til min podkast og tusen takk for at du lytter (og ser på)

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Political Editor Jo Moir spoke to Lisa Owen about the resignations of Reserve Bank head Adrian Orr and Air New Zealand CEO Greg Foran, as well as the sacking of UK High Commissioner Phil Goff.

There's a belief outgoing Air New Zealand boss Greg Foran's lack of aviation experience may have hurt his career. He's announced he'll leave the company in October. Foran's told his board the time's right to step down, and the airline is well set up for the future. Forsyth Barr head of research, Andy Bowley told Mike Hosking Foran's had to deal with Covid, a national recession, and engine maintenance issues throughout his tenure. He says it's also been the biggest period of inflation seen in a generation, which added up, has been pretty challenging. The company will also have little trouble finding a new CEO. Bowley told Hosking the company has a history of attracting talented people for the role from around the world. He says they're typically Kiwis, who have learnt their trade offshore. The CEO before Foran was none other than now Prime Minister Christopher Luxon. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Air New Zealand is in for a change - with CEO Greg Foran resigning from October. He's told the board the airline is in a good place and this is the right time to step down. He took on the role in February 2020. Aviation commentator Irene King says the airline should take this opportunity to restore confidence at home. "Air New Zealand has really got to focus on its core New Zealand market - and I think some of that's been lost. The edge has gone off." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Tonight on The Huddle, Kiwiblog's David Farrar and former Labour minister Stuart Nash joined in on a discussion about the following issues of the day - and more! Foreign Minister Winston Peters made the decision to sack Phil Goff as High Commissioner to the UK after he questioned President Donald Trump's understanding of history. Was this the right call? The Government has revealed it plans to lower the age of eligibility for free bowel cancer screenings to 58. However, it's using funding set aside from the last Government's plan to lower screening for Māori and Pasifika to 50. What do we make of this? Air New Zealand CEO Greg Foran has officially resigned - and will step down from the role this October. How will he be remembered? Did he make the right call? LISTEN ABOVESee omnystudio.com/listener for privacy information.

There's a belief Air New Zealand should turn its focus back on serving domestic customers as it looks for a new CEO. Greg Foran has resigned after five years in the job, but he's staying on in the role until October. He says the airline was set up well to continue its growth and innovation. Aviation Commentator Irene King told Andrew Dickens they've got to be really focused on the domestic market. She says customers are unhappy, and they perceive they're not getting value for money. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Air New Zealand is in for a change - with CEO Greg Foran resigning from October. He's told the board the airline is in a good place and this is the right time to step down. He took on the role in February 2020. Aviation commentator Irene King says the airline should take this opportunity to restore confidence at home. "Air New Zealand has really got to focus on its core New Zealand market - and I think some of that's been lost. The edge has gone off." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Mandag aften gæstede statsminister Mette Frederiksen Jyllands-Posten til en samtale med chefredaktør Marchen Neel Gjertsen om den meget alvorlige situation, verden befinder sig i. Foran en sal fuld af Jyllands-Postens læsere gav hun sig selv titlen »oprustningsstatsminister« og svarede på, om hun stadig har tillid til Nato. I denne særudgave giver vi dig en unik mulighed for at være fluen på væggen, så du kan høre statsministerens svar på, hvordan Danmark skal navigere i den nye verdensorden, og om det er tid til en europæisk hær. Gæst: Mette Frederiksen (S), statsminister Vært: Marchen Neel Gjertsen, chefredaktør på Jyllands-Posten Klip og produktion: Asbjørn Kjærgaard-Pedersen Foto: Casper Dalhoff See omnystudio.com/listener for privacy information.

Jack Foran + Auntie Brenda + Kemba | QUIVR | 15-02-25 by QUIVR

I går kveld gikk USA offisielt av som leder for den frie verden. Foran åpne TV-kameraer kunne alle se hvilken avgrunn det er mellom Ukraina og USA under president Donald Trump. Med Anders Giæver, Frøy Gudbrandsen og Hanne Skartveit. Produsent Magne Antonsen. Ansvarlig redaktør Gard Steiro. Kontakt redaksjonen på giaeveroggjengen@vg.no. Giæver & gjengen gir deg de viktigste nyhetene hver dag på drøye 20 minutter når du skal hjem fra jobb. Hør «Mediebobler» hver lørdag om feilene pressen gjør og dilemmaer VG står i. Hør «Skartveit» med interessante personer om aktuelle temaer hver søndag. Alltid på Podme.

Onsdag aften mødtes Politikens chefredaktør Christian Jensen og hundrede læsere i Politikens foredragssal for at tale med statsminister Mette Frederiksen om Europas fremtid og Danmarks vej gennem en fortsat mere usikker tid. Du kan høre samtalen i sin helhed her.See omnystudio.com/listener for privacy information.

Send us a textOn this episode of Induced Fear, Jeff Foran of Strangeology joins to share his work in the paranormal and his content he creates. Jeff also shares his personal experiences that brought him into the strange world of the paranormal along how his views have changed as time went on.From a spirit in his childhood home to and a glowing orb floating through the woods!Jeff Foran's/Strangeology Website:https://www.strangeology.com/

Air New Zealand expects to be short of planes for at least another two or three years. Our national carrier's recording an 18% drop in half-year profit. That follows a 65% in full-year profit last year. Chief Executive Greg Foran told Mike Hosking they're going into a period when up to 11 aircrafts will be out of action. He says it's a bit like playing a rugby match without the front row. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Air New Zealand is brushing off criticism from Aotearoa's largest airport. Auckland Airport CEO Carrie Hurihanganui has suggested the national carrier's too dominant in the domestic market, holding an 84 percent market share. She stated Air New Zealand wasn't meeting the needs of consumers or the regions. Its Chief Executive, Greg Foran says there've been adjustments in recent months - particularly Wellington - with declines in Government and corporate travel. "But we know how important it is to be fair to everyone in New Zealand and ensure we've got connectivity." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Greg Foran is the CEO of Air New Zealand – and one of the country's most successful businessmen.Greg started his career as a shelf-stacker in a Hamilton supermarket. By the age of 20 he was a Woolworths manager and by 48 he was on track to be the next CEO of Woolworths Australia – but was overlooked for the top job.He pivoted to America via China where he started working his way up the Walmart ladder and in 2014 became the CEO of Walmart US.As CEO of Walmart US – Greg had 1.5 million staff, 4,600 stores across the country and an annual GDP of 300 billion. This was a Kiwi running America's biggest retailer.Then in 2020, Greg left Walmart to move home to New Zealand and took the top job at Air New Zealand… just days before Covid-19 started grounding flights.This was a fascinating chat – and we think you'll quickly be able to see why Greg has had the career he's had.If you'd like to get one of our epic guests in to MC or Speak at your function or event, flick us a message by going to B2Bspeakers.co.nz.This episode is brought to you by TAB, download the new app today and get your bet on!Between Two Beers is now part of the Acast Creator Network, listen wherever you get your podcasts from, or watch the video on YouTube.Enjoy. Hosted on Acast. See acast.com/privacy for more information.

In the latest of WRN weekly zooms made publicly available, Heather Binning talks with Dr Michael Foran, a Lecturer in Public Law at The University of Glasgow, who specialises in constitutional and discrimination law. Beginning with how Michael "accidently" entered the sex and gender debate they discuss the complexities of law in this area, including the implications of a judgement in the For Women Scotland vs Scottish Ministers case, heard at the Supreme Court in November last year, before taking questions from a gripped audience of Women's Rights Network members. 

"Green Witch" Feebee Foran tells PJ about the profound impact of her father's passing and how it led to her embracing healing and natureSee Feebee Wed Feb 5th 7.30 at the Metropole book here Hosted on Acast. See acast.com/privacy for more information.

Foran fuldt hus på Bremen Teater i København gik Rune Lykkeberg og Bjarne Corydon på scenen mandag eftermiddag. Det var lige inden, at Donald Trump blev genindsat som amerikansk præsident.  På dramaskalaen vurderer chefredaktørerne genvalget af Donald Trump over murens fald. Rune Lykkeberg hæfter sig ved, at Trump står for det modsatte af det, som den frie verden er bygget på og frygter især hvad han vil gøre på klimafronten. Bjarne Corydon sætter klimaet på andenpladsen, mens usikkerheden om hvad der sker sikkerhedspolitisk er nr. 1.  De slutter af med hvad man kan håbe på ved Trump - Corydon er den mest optimistiske, mens Lykkeberg har svært ved at kæde håb sammen med USA's præsident.  Producer: Arjuna Alexander Kolkur Sørensen

Latest developments from the deadly wildfires in Southern California, and community and supporting your community in the midst of a crisis.

I denne episoden av Filmfrelst møter vi regissør og manusforfatter Kenneth Karlstad, som har basert kultserien Kids in Crime (2022-) på egne erfaringer fra ungdomstiden. Den andre sesongen av Kids in Crime hadde premiere på TV2 sent høsten 2024, med enda høyere kunstneriske ambisjoner enn den første. Episodene bærer preg av at Karlstad vil eksperimentere og ta noen solide sjanser, og i denne praten får vi grundig innsikt i arbeidet bak og hva slags typer, skjebner og historier som er utgangspunktet for dette rusa Sarpsborg [Sasjbårr]-universet. Det blir også tid til noen røverhistorier. Foran mikrofonene sitter to østfoldinger, redaktør Lars Ole Kristiansen og Kenneth Karlstad. God lytting!

Det er den 5. oktober 1916. Den svenske opdagelsesrejsende og botaniker Carl Skottsbergstævner ud fra Göteborg. Han vil til Sydamerika. Ud på Juan Fernandaz-øerne og ud på denmytiske Påskeø, hvor de gådefulde kæmpestatuer ligger spredt ud over vulkanøen.Skottsberg drømmer om at finde en ny flora. Foran ham ligger en spændende, begivenhedsrigog til tider nervepirrende rejse, hvor han frygter at strande på en øde ø - præcis somvirkelighedens Robinson Crusoe.Medvirkende:Jens Soelberg, ph.d. med speciale i etnobotanik, biokulturelle samlinger, botanisk lægemiddelhistorie og arbejder i de botaniske samlinger på Statens Naturhistorisk Museum.Denne sæson af Den Yderste Grænse er produceret i et samarbejde mellem Nationalmuseets mediehus Vores Tid og Statens Naturhistoriske Museum. 

Kjøp billetter til LIVESHOWET 25. Januar her: ⁠⁠https://www.ticketmaster.no/event/aktiv-prat-liveshow-billetter/1823952204⁠ Vi starter det nye året med en ny episode! Kan jenter være wingmen? Er det attraktivt med jenter som vet hva de vil? Er piercing i nesa egentlig ganske sexy? Kan man være sammen med noen som synger som en kaldkvelt katt? Fiser jenter foran hverandre, og hva gjør man når dama til kompisen spør om trekant? Anonymt skjema for innsendelser: ⁠⁠⁠⁠⁠https://forms.gle/j9rAaF7jvgsHWoiS6⁠

In this heartfelt and inspiring episode, Emma Foran takes us on her journey of self-discovery, career transformation, and personal growth. From her early aspirations to be an actor to navigating unfulfilling corporate roles, Emma shares how she found her true calling in social care and her current role as an Employment Officer at Down Syndrome Ireland.Emma reflects on the invaluable lessons she learned growing up alongside her aunt, who has Down Syndrome, and how it shaped her compassionate outlook on life. She discusses the challenges of leaving stable corporate jobs to pursue meaningful work and the joy she now finds in empowering adults with Down Syndrome to thrive in employment.Emma also opens up about the importance of living authentically, the struggles of societal expectations, and her evolving relationship with social media. With warmth and honesty, Emma reveals how embracing her passions has brought her a deep sense of purpose and fulfillment.If you've ever questioned your career path, struggled with conformity, or sought inspiration to make a meaningful change, this episode is for you.Let me know your thoughts on this eposideWebsiteInstagram TwitterFacebook

Foran en jernlåge ind til sit familiegravsted står Line. Bag jernlågen ligger en hemmelighed begravet, der ikke kun vil forandre hendes liv. Den vil også omskrive en lang række menneskers livshistorie, hvor de vil sande, at deres tidlige barndomsminder er falske. Genstart sender i dag 1. afsnit af DRs nye dokumentarserie 'Falske minder' som kaster lys over hidtil hemmeligholdte oplysninger om den danske stats involvering i det eksperter kalder bestikkelse og handel med spædbørn. Program publiceret i DR Lyd d. 22/12.

Vi er live! Foran et fantastisk publikum i Stavangeren snakkes det om juletradisjoner, heltedåder og annet julesnacks. Og vi har gjest! Han er tidligere toppidrettsutøver, som nå gjør stor suksess som standup-komiker. Hos oss snakker han om hvordan følelser ble mottatt i en hockeygarderobe, hva som gjør han sint og glad, og selvfølgelig hvordan det var å gå Norge på langs med kamera på slep. Og Per har skrevet juledikt! Hjertelig velkommen! Hosted on Acast. See acast.com/privacy for more information.

It's been a turbulent year for Air New Zealand, who have dealt with ongoing engine maintenance issues, back lash over prices, cuts to regional routes and plummeting profits . MPs and some mayors have given the national carrier a serve for cuts to what they say are "vital" services. Air New Zealand has been forced to suspend its direct flights to Chicago over maintenance issues with the Rolls Royce trent 1000 engines on its 787 Dreamliners, following concerns of premature wear and weakness. Air New Zealand CEO, Greg Foran spoke to Lisa Owen.

Air New Zealand's chief executive says it's a matter of when, not if, they return to London. The airline faces another two to three years of disruption waiting for new aircraft and the completion of maintenance on existing ones. The disruptions already cost the airline up to $150 million a year. Greg Foran told Heather du Plessis-Allan they've been given spots at Gatwick Airport. He says it got them excited initially, but they haven't got any planes. Greg Foran says he expects to get those planes at the start of 2026. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Send us a textWhat if embracing gratitude could transform not just your personal life, but your professional world too? Join us as we chat with Steve Foran, an electrical engineer who turned his career towards advocating for grateful leadership. Together, we unravel our personal gratitude rituals—like my daily practice of sending out gratitude lists and Steve's habit of emailing his daily gratitudes. We explore the ripple effects that sharing gratitude can have, not only uplifting ourselves but also spreading positivity to those around us. We dive into how the simple act of recording gratitude can bolster personal growth and even reshape our brains. I share my own journaling technique that follows a daily theme, while Steve and I discuss framing gratitude as both personal benefit and recognition of others' sacrifices. This dual perspective helps us appreciate our interconnections and the present moment. We also reflect on the challenges of weaving gratitude into the fabric of busy lives and workplaces, where it can enhance human connections and shift perspectives, ultimately creating a thriving workplace culture.Finally, we talk about the role of gratitude in professional networking and the delicate balance between public expression and intimate sincerity. Sharing personal stories of vulnerability, including my own journey through loss and Steve's experiences with overcoming alcoholism, we underscore the courage required to share openly. Tune in to discover how gratitude can fortify bonds, encourage vulnerability, and offer insights into what truly matters, inspiring you to kickstart your own gratitude practice and make genuine connections in all areas of life.Steve ForanSteve@gratitudeeatwork.cahttp://www.gratitudeatwork.cahttp://linkedin.com/in/steveforangratefulceo Support the show https://www.audible.com/pd/9-Simple-Steps-to-Sell-More-ht-Audiobook/B0D4SJYD4Q?source_code=ASSORAP0511160006&share_location=library_overflowhttps://www.amazon.com/Simple-Steps-Sell-More-Stereotypes-ebook/dp/B0BRNSFYG6/ref=sr_1_1?crid=1OSB7HX6FQMHS&keywords=corey+berrier&qid=1674232549&sprefix=%2Caps%2C93&sr=8-1https://bit.ly/4bFz4yc https://www.housecallpro.com/successullifehttps://www.facebook.com/corey.berrier https://www.linkedin.com/in/coreysalescoach/

Air New Zealand's head is defending splashing out on a new safety video, as airfares rise. Kiwi NBA player Steven Adams features in the airline's first safety video in two years, alongside cameos by other notable Kiwis. Chief executive Greg Foran says this is a worthwhile investment. "It's an important part of the brand, it's a bit like the mangōpare on the tail or the uniforms - and we're doing a new one and you'll see them next year." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Hva gjør en dommer – og hva gjør en rettsmekler? Nylig var det åpent hus i Høyesterett, lagmannsretten og tingretten på «Rettens dag». Foran et nysgjerrig rettssalspublikum i Borgarting spurte Anine lagdommerne Ingvild Mestad og Frode Elgesem om hva som preger dommerrollen og hvem som egentlig får dommerhverdagen til å gå rundt. Ingvild forklarer også hva rettsmekling er, og hvorfor det ofte er et ganske smart alternativ til en ankeforhandling. Visste du at nesten 80% av sakene som mekles i Borgarting blir forlikt? Rettens dag | Norges domstolerEuropean Day of Justice - European Commission for the Efficiency of Justice (CEPEJ)Borgarting arsmelding-2023.pdf Hosted on Acast. See acast.com/privacy for more information.

Foran Mining Corporation (TSX: FOM | OTCQX: FMCXF), a copper-zinc-gold-silver exploration and development company, is on a mission to discover and produce critical minerals to support global decarbonization and generate long-term value.Vice President of Capital Markets and External Affairs Jonathan French sits down with us to discuss the development of Foran Mining's McIlvenna Bay Critical Mineral Development Project in Saskatchewan, Canada, which is anticipated to reach commercial production in H1 2026. He also shares upcoming milestones and highlights what makes the company a stock to watch.Discover Foran Mining and its Mcllvenna Bay Project: https://foranmining.com/For more insights, catch Vox Royalty at the upcoming Commodities Global Expo 2024 at Four Seasons Fort Lauderdale, Florida on October 20 to 22 (https://topshelf-partners.com). This event and interview is brought to you by Feneck Consulting Group (https://www.feneckconsulting.com).Watch the full YouTube interview here: https://www.youtube.com/watch?v=MTqbAsPM-AYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

Foran en fuld sal af USA-interesserede på Jyllands-Posten i Aarhus zoomer Mads Fuglede og David Trads ind på, hvem det egentlig er, der stemmer på Trump - og endnu mere hvorfor de gør det? Og så fortæller de om, hvad den enorme forandring af befolkningssammensætninger giver af brydninger.See omnystudio.com/listener for privacy information.

In the second part of our Air New Zealand conversation, we put your questions to CEO Greg Foran. Things like: why pay a dividend if things are so tough? Will airfares come down? How is the cost of living crisis affecting how we fly?For more or to watch on youtube—check out http://linktr.ee/sharedlunch Investing involves risk. This episode is brought to you by Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) in Australia and Sharesies Limited (NZ) in New Zealand. Information provided is general only and current at the time and does not take into account your circumstances, objectives or needs. We do not provide recommendations and you should always read the disclosure documents available to the product's issuer before making a financial decision. Our disclosure documents, including a Target Market Determination for Sharesies, can be found on our website. If you require financial advice, you should consider speaking with a qualified financial advisor. The views expressed by individuals are their own and Sharesies does not endorse any of the guests or the views they hold. See omnystudio.com/listener for privacy information.

We chew on the headwinds the national carrier is battling and what it's doing to fly a smoother path with CEO Greg Foran.  Our conversation follows a 65% drop in net profit and earnings down by more than half for the 2024 financial year, plus no guidance due to uncertainty ahead.  But Greg Foran is candid about how resourceful a little airline at the bottom of the world needs to be to ride out fleet and maintenance issues, and an economic downturn.  We ask him about his tenure since early 2020 and what he'd do differently? And when will the airline be flying into London after an absence of 5 years?  For more or to watch on youtube—check out http://linktr.ee/sharedlunch Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own. Shared Lunch is not financial advice. We recommend talking to a licensed financial adviser. You should review relevant product disclosure documents before deciding to invest. Investing involves risk. You might lose the money you start with. Content is current at the time. See omnystudio.com/listener for privacy information.

GOOD EVENING: The show begins in Las Vegas to look to the future foran MLB stadium and the new Hard Rock Hotel and Casino..,. undated Out CBS EYE ON THE WORLD WITH JOHN BATCHELOR FIRST HOUR 9-915 #PacificWatch: #VegasReport: Mirage and Tropicana replaced by Hard Rock Hotel and MLB. @JCBliss 915-930 #MEXICO: AMLO on the eve of control as the peso retreats. Mary Anastasia O'Grady, WSJ 930-945 #SCOTUS: Immunity and the Special Counsel. Dodd Frank and the Special Counsel Richard Epstein, Hoover. 945-1000 #POTUS: "Freedom" at the DNC. Richard Epstein, Hoover.  SECOND HOUR 10-1015 #POTUS: Harris White House can reward California with the 2028 DNC Convention in LA. Bill Whalen, Hoover Institution. 1015-1030 #LANCASTER REPORT: Shopping nothing but discounts galore: Jim McTague, former Washington Editor, Barrons. @MCTagueJ. Author of the "Martin and Twyla Boundary Series." #FriendsofHistoryDebatingSociety 1030-1045 #SPACEX: Grounded for a barge landing anomaly. Bob Zimmerman BehindtheBlack.com 1045-1100 #NASA: Troubled Europa Clipper to fly. Bob Zimmerman BehindtheBlack.com THIRD HOUR 1100-1115 1/4: When China Attacks: A Warning to America by Grant Newsham (Author) https://www.amazon.sg/When-China-Attacks-Warning-America/dp/1684513650 Communist China is ambitious. It wants to replace the United States as the world's leading superpower. And it is well on its way. It is dominant in the world economy. It is a master at intellectual property theft. It shows strategic genius at cornering essential markets. It has been staggeringly successful in buying influence among American elites. And its military buildup is astonishing. So far, China has been waging a cold war on the United States and its Asian allies. But, emboldened by American weakness and decline, that cold war is about to turn hot. The flashpoint will be Taiwan—but the war will extend over the entire Pacific Theatre. The results could be devastating. America is facing the possibility of humiliating regional retreat—one with almost unimaginable costs to our economy and security. That's the warning of Grant Newsham, a longtime China analyst for the Marine Corps, the Foreign Service, and Morgan Stanley Bank in Japan. His shocking new book *When China Attacks* is a fire bell in the night—a warning about an imminent hot war that we are already in the process of losing. It offers a frightening, but well-founded, blow-by-blow account of what might happen.  1115-1130 2/4: When China Attacks: A Warning to America by Grant Newsham (Author) 1130-1145 3/4: When China Attacks: A Warning to America by Grant Newsham (Author) 1145-1200 4/4: When China Attacks: A Warning to America by Grant Newsham (Author) FOURTH HOUR 12-1215 #Non-Proliferation: What is to be done IN THE US, IRAN, SAUDI ARABIA, RUSSIA, CHINA? Henry Sokolski, NPEC 1215-1230 #RUSSIA: #PRC: Cold War in LEO. Henry Sokolski, NPEC 1230-1245 #ELECTRICITY: Generac to the rescue of a power hungry and starved 21st. Robert Bryce.  1245-100 am #ITALY: Hollywood on the Palatine. Lorenzo Fiori, Ansaldo Foundation.